MOUNTAIN VIEW, Calif., May 15 AlexzaPharmaceuticals, Inc. (Nasdaq: ALXA) announced today that Carlos A. Parra hasjoined the company as Vice President, Quality. He will have responsibilitiesin the development and execution of quality program strategies for Alexza'smanufacturing operations and preclinical / clinical product candidates. Mr.Parra was most recently Vice President, Operations and Quality at Telik, Inc.in Palo Alto, California, where he was employed since June 2002 and wasresponsible for all aspects of GxP pharmaceutical development and qualityoperations, including manufacturing development and GCP compliance.
Prior to his tenure at Telik, Mr. Parra was a Principal Partner at WestCoast Associates from January 1996 to June 2002. Before founding West CoastAssociates, his quality experience spanned 20 years with both small and largepharmaceutical and biotechnology companies. Mr. Parra holds a Bachelor's ofScience in Microbiology with a minor in Engineering from the University ofTexas at El Paso.
"We are very pleased to welcome Carlos to Alexza to lead our QualityDepartments and as a member of our Management Team," said Thomas B. King,Alexza President and CEO. "The continued rapid growth of our clinical andpreclinical programs at Alexza requires us to add integrated GLP and GCPquality systems and procedures to our existing GMP program. Carlos brings awealth of U.S. and international quality expertise to Alexza, and we lookforward to his contributions to our future development."
About Alexza Pharmaceuticals
Alexza Pharmaceuticals is an emerging specialty pharmaceutical companyfocused on the development and commercialization of novel, proprietaryproducts for the treatment of acute and intermittent conditions. TheCompany's technology, the Staccato(R) system, vaporizes unformulated drug toform a condensation aerosol that allows rapid systemic drug delivery throughdeep lung inhalation. The drug is quickly absorbed through the lungs into thebloodstream, providing speed of therapeutic onset that is comparable tointravenous administration, but with greater ease, patient comfort andconvenience.
Alexza has six product candidates in clinical development. Alexza's leadprogram, AZ-004 (Staccato loxapine) for the treatment of acute agitation inschizophrenic or bipolar disorder patients, is in Phase 3 testing. AZ-001(Staccato prochlorperazine) for the acute treatment of migraine headaches hascompleted Phase 2 testing. AZ-104 (Staccato loxapine) for the acute treatmentof migraine headaches and AZ-002 (Staccato alprazolam) for the acute treatmentof panic attacks associated with panic disorder are in Phase 2 testing.Product candidates in Phase 1 testing include AZ-003 (Staccato fentanyl) forthe treatment of breakthrough pain, which is partnered with EndoPharmaceuticals in North America, and AZ-007 (Staccato zaleplon) for thetreatment of insomnia. More information, including this and past pressreleases from Alexza is available online at http://www.alexza.com.
SOURCE Alexza Pharmaceuticals, Inc.